---
title: "Sight Sciences publishes investor presentation on interventional glaucoma, dry eye platforms"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295025201.md"
description: "Sight Sciences outlined a strategy to expand procedural eye-care offerings for glaucoma and dry eye, targeting earlier intervention. Management projects a return to double-digit revenue growth in 2026, supported by strong gross margins and disciplined expense control. The company highlighted progress in TearCare reimbursement with new Medicare fee schedules. To date, Sight Sciences has performed over 400,000 interventional glaucoma procedures and 75,000 interventional dry eye procedures."
datetime: "2026-08-05T22:34:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295025201.md)
  - [en](https://longbridge.com/en/news/295025201.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295025201.md)
generator: "portal-rs"
---

# Sight Sciences publishes investor presentation on interventional glaucoma, dry eye platforms

-   Sight Sciences outlined a strategy to expand procedural eye-care offerings across glaucoma and dry eye, targeting earlier intervention versus daily eye drops. \* Management flagged a return to double-digit revenue growth in 2026, supported by strong gross margins and disciplined operating expense control. \* TearCare reimbursement progress highlighted, with the first two Medicare Administrative Contractors establishing fee schedules to support market access. \* Installed base cited at more than 400,000 interventional glaucoma procedures, more than 75,000 interventional dry eye procedures performed to date. \* Dry eye market size estimated at USD 2.4 billion in the US, versus a USD 6 billion addressable US glaucoma market with more than 4 million diagnosed patients. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sight Sciences Inc. published the original content used to generate this news brief on August 05, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [SGHT.US](https://longbridge.com/en/quote/SGHT.US.md)

## Related News & Research

- [Sight Sciences Q2 revenue rises 20%, beats estimates](https://longbridge.com/en/news/295013505.md)
- [Sight Sciences Receives FDA 510(k) Clearance of the OMNI Ultra Surgical System | SGHT Stock News](https://longbridge.com/en/news/294876777.md)
- [Bausch + Lomb unveils new ESCRS clinical data on enVista Aspire, LuxLife IOLs, ELIOS glaucoma procedure](https://longbridge.com/en/news/297903773.md)
- [Kala Bio signs LOI for exclusive US distribution of Virotek ophthalmology genetic tests](https://longbridge.com/en/news/297646733.md)
- [07:57 ETOrbis Flying Eye Hospital Marks 20 Years of Partnership with Macau](https://longbridge.com/en/news/298034653.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**